Enobia Completes Patient Enrolment for Bone Disorder Drug Study

28 February 2011 (Last Updated February 28th, 2011 18:30)

Enobia Pharma has completed patient enrolment for a Phase II study evaluating ENB-0040 as a treatment for hypophosphatasia, a rare metabolic bone disorder. The study will evaluate ENB-0040 in adolescents and adults with the comdition. On its completion, which is anticipated later this

Enobia Pharma has completed patient enrolment for a Phase II study evaluating ENB-0040 as a treatment for hypophosphatasia, a rare metabolic bone disorder.

The study will evaluate ENB-0040 in adolescents and adults with the comdition. On its completion, which is anticipated later this year, the company will have collected safety and efficacy data for ENB-0040 in hypophosphatasia patients of all ages.

ENB-0040 was granted orphan designation in the US and EU in 2008 and fast-track status in 2009. If approved, it would be the first treatment for hypophosphatasia.

Hypophosphatasia is a rare genetic disease characterised primarily by defective bone mineralisation caused by a deficiency in the enzyme tissue non-specific alkaline phosphatase.